ALNY - Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

• Alnylam Pharmaceuticals ( NASDAQ: ALNY ) said that a phase 2 trial of its RNAi therapeutic cemdisiran for immunoglobulin A nephropathy achieved positive results .
• Results previously showed that at week 32, cemdisiran demonstrated a clinically meaningful reduction in 24-hour urine protein. This was the study's primary endpoint
• New data demonstrated that cemdisiran led to reduction in 24-hour urine total protein and a higher proportion -- 32% versus 13% -- of patients treated with cemdisiran as compared to those on placebo achieving greater than or equal to 50 percent reduction in 24-hour urine protein to creatinine ratio.
• Cemdisiran was generally well tolerated with with no adverse events leading to treatment or study discontinuation in participants.
• Seeking Alpha's Quant Rating views Alnylam ( ALNY ) as a hold with strong grades for momentum and profitability .

For further details see: